These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7840184)

  • 1. In vivo insulin mimetic effects of pV compounds: role for tissue targeting in determining potency.
    Bevan AP; Burgess JW; Yale JF; Drake PG; Lachance D; Baquiran G; Shaver A; Posner BI
    Am J Physiol; 1995 Jan; 268(1 Pt 1):E60-6. PubMed ID: 7840184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A stable peroxovanadium compound with insulin-like action in human fat cells.
    Eriksson JW; Lönnroth P; Posner BI; Shaver A; Wesslau C; Smith UP
    Diabetologia; 1996 Feb; 39(2):235-42. PubMed ID: 8635677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxovanadium compounds: biological actions and mechanism of insulin-mimesis.
    Bevan AP; Drake PG; Yale JF; Shaver A; Posner BI
    Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):49-58. PubMed ID: 8927047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen).
    Band CJ; Posner BI; Dumas V; Contreres JO
    Mol Endocrinol; 1997 Dec; 11(13):1899-910. PubMed ID: 9415395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A peroxovanadium compound stimulates muscle glucose transport as powerfully as insulin and contractions combined.
    Nolte LA; Han DH; Hansen PA; Hucker KA; Holloszy JO
    Diabetes; 2003 Aug; 52(8):1918-25. PubMed ID: 12882906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics.
    Posner BI; Faure R; Burgess JW; Bevan AP; Lachance D; Zhang-Sun G; Fantus IG; Ng JB; Hall DA; Lum BS
    J Biol Chem; 1994 Feb; 269(6):4596-604. PubMed ID: 8308031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxovanadate and insulin action in adipocytes from NIDDM patients. Evidence against a primary defect in tyrosine phosphorylation.
    Yu ZW; Jansson PA; Posner BI; Smith U; Eriksson JW
    Diabetologia; 1997 Oct; 40(10):1197-203. PubMed ID: 9349602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxyvanadium compounds inhibit glucose-6-phosphatase activity and glucagon-stimulated hepatic glucose output in the rat in vivo.
    Westergaard N; Brand CL; Lewinsky RH; Andersen HS; Carr RD; Burchell A; Lundgren K
    Arch Biochem Biophys; 1999 Jun; 366(1):55-60. PubMed ID: 10334863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line.
    Faure R; Vincent M; Dufour M; Shaver A; Posner BI
    J Cell Biochem; 1995 Nov; 59(3):389-401. PubMed ID: 8567756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for tyrosine phosphorylation in both activation and inhibition of the insulin receptor tyrosine kinase in vivo.
    Drake PG; Bevan AP; Burgess JW; Bergeron JJ; Posner BI
    Endocrinology; 1996 Nov; 137(11):4960-8. PubMed ID: 8895369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-mimetic agents vanadate and pervanadate stimulate glucose but inhibit amino acid uptake.
    Tsiani E; Abdullah N; Fantus IG
    Am J Physiol; 1997 Jan; 272(1 Pt 1):C156-62. PubMed ID: 9038821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin receptor kinase-associated phosphotyrosine phosphatases in hepatic endosomes: assessing the role of phosphotyrosine phosphatase-1B.
    Li C; Baquiran G; Gu F; Tremblay ML; Fazel A; Bergeron JJ; Posner BI
    Endocrinology; 2006 Feb; 147(2):912-8. PubMed ID: 16269466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of peroxovanadate and vanadate on insulin binding, degradation and sensitivity in rat adipocytes.
    Yu ZW; Posner BI; Smith U; Eriksson JW
    Biochim Biophys Acta; 1996 Jan; 1310(1):103-9. PubMed ID: 9244182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A peroxovanadium compound induces Xenopus oocyte maturation: inhibition by a neutralizing anti-insulin receptor antibody.
    Cummings C; Zhu L; Sorisky A; Liu XJ
    Dev Biol; 1996 May; 175(2):338-46. PubMed ID: 8626037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity nor phosphorylation in mouse diaphragm in vivo.
    Strout HV; Vicario PP; Saperstein R; Slater EE
    Endocrinology; 1989 Apr; 124(4):1918-24. PubMed ID: 2647469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective activation of the rat hepatic endosomal insulin receptor kinase. Role for the endosome in insulin signaling.
    Bevan AP; Burgess JW; Drake PG; Shaver A; Bergeron JJ; Posner BI
    J Biol Chem; 1995 May; 270(18):10784-91. PubMed ID: 7537739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxovanadium-mediated protection against murine leishmaniasis: role of the modulation of nitric oxide.
    Matte C; Marquis JF; Blanchette J; Gros P; Faure R; Posner BI; Olivier M
    Eur J Immunol; 2000 Sep; 30(9):2555-64. PubMed ID: 11009089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle.
    Lai YC; Liu Y; Jacobs R; Rider MH
    Biochem J; 2012 Oct; 447(1):137-47. PubMed ID: 22793019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats.
    Yale JF; Lachance D; Bevan AP; Vigeant C; Shaver A; Posner BI
    Diabetes; 1995 Nov; 44(11):1274-9. PubMed ID: 7589823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition Effects of Some Bioactive Peroxovanadium Complexes on the Tyrosine Phosphatase.
    Zhou XW; Chen Z; Chen QX; Ye JL; Huang PQ; Wu QY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2000; 32(2):133-138. PubMed ID: 12098789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.